From investor presentation March 2015 for capital raising.
Use of funds > These funds are budgeted to last until the end of Q3 2015 which will be following the expected release of pivotal clinical data relating to the INV103 (ala-Cpn10) and INV102 (nadolol) programs (anticipated within 3-4 months). It is expected that positive clinical data from one or both of these trials will position the company to negotiate a strategic investment in the company by a recognised biotech fund or provide a platform for a trade sale of the company or its assets.
Cash position, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $25.69M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $4.849K | 1.212M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 27580409 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 8225728 | 26 |
View Market Depth
| Last trade - 12.46pm 25/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |